Investigational drug · Phase 3
VIR-3434
Also called: Tobevibart
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Viral Hepatitis, Hepatitis D, Chronic, Hepatitis B, Chronic.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
10
Any phase or sponsor naming "VIR-3434"
First trial start
2021
Jul 11, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VIR-3434", any sponsor or status.
Conditions studied
As listed on its trial records.
- Viral Hepatitis
- Hepatitis D, Chronic
- Hepatitis B, Chronic
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "VIR-3434" as an intervention, largest first.
- Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionCompleted
Vir Biotechnology, Inc.Industry
NCT04856085 · 244 participants · Start Jul 11, 2021 · Primary completion Mar 16, 2026
Drug: VIR-2218; VIR-3434 and 1 more · For: Hepatitis B, Chronic
Sites: San Francisco, California; Miami, Florida; Orlando, Florida · 37 sites in all
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtidePivotal-lookingActive, not recruiting
Vir Biotechnology, Inc.Industry
NCT07128550 · 150 participants (planned) · Start Jul 30, 2025 · Primary completion Dec 2026
Drug: Tobevibart; Elebsiran and 1 more · For: Viral Hepatitis
Sites: Innsbruck, Austria; Vienna, Austria; Bobigny, France · 38 sites in all
- A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionPivotal-lookingActive, not recruiting
Vir Biotechnology, Inc.Industry
NCT06903338 · 124 participants · Start Mar 12, 2025 · Primary completion Sep 30, 2026
Drug: Tobevibart; Elebsiran · For: Viral Hepatitis
Sites: Chandler, Arizona; Los Angeles, California; Redwood City, California · 39 sites in all
- Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus InfectionPivotal-lookingCompleted
Vir Biotechnology, Inc.Industry
NCT04423393 · 113 participants · Start May 26, 2020 · Primary completion Oct 24, 2022
Drug: VIR-3434 · For: Chronic Hepatitis B
Sites: Essen, Germany; Frankfurt, Germany; Hanover, Germany · 24 sites in all
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionPivotal-lookingActive, not recruiting
Vir Biotechnology, Inc.Industry
NCT07142811 · 100 participants (planned) · Start Aug 5, 2025 · Primary completion Mar 2029
Drug: Tobevibart; Elebsiran and 1 more · For: Viral Hepatitis
Sites: Brussels, Belgium; Edegem, Belgium; Sofia, Bulgaria · 27 sites in all
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.Active, not recruiting
Vir Biotechnology, Inc.Industry
NCT05461170 · 95 participants · Start Sep 17, 2022 · Primary completion Nov 2031
Drug: VIR-2218; VIR-3434 and 1 more · For: Hepatitis D, Chronic
Sites: Sofia, Bulgaria; Stara Zagora, Bulgaria; Clichy, France · 20 sites in all
Vir Biotechnology, Inc.Industry
NCT05484206 · 88 participants · Start Sep 21, 2022 · Primary completion Dec 9, 2025
Drug: VIR-2218; VIR-3434 · For: Hepatic Impairment; Cirrhosis
Sites: Rialto, California; Tustin, California; Miami Lakes, Florida · 4 sites in all
Virion TherapeuticsIndustry
NCT06070051 · 35 participants · Start Sep 26, 2023 · Primary completion Mar 31, 2026
Drug: VRON-0200-AdC6; VRON-0200-AdC7 and 2 more · For: Chronic Hepatitis B
Sites: Hong Kong, Hong Kong; Auckland, New Zealand · 3 sites in all
Vir Biotechnology, Inc.Industry
NCT05612581 · 33 participants · Start May 10, 2023 · Primary completion Oct 15, 2024
Drug: VIR-3434; VIR-2218 and 2 more · For: Hepatitis B, Chronic
Sites: Clichy, France; Nice, France; Rennes, France · 15 sites in all
University Health Network, TorontoAcademic, hospital or other
NCT06216470 · 15 participants (planned) · Start Mar 13, 2024 · Primary completion Dec 2029
Drug: VIR-3434 · For: Hepatitis B, Chronic
Sites: Toronto, Canada
Newest research
PubMed records naming it or its code names, newest first.
- New Paradigms in Hepatitis D: Screening, Treatment, and the Path to Cure.
Herta T, Gaebler C, Wiegand J, et al. · Semin Liver Dis 2026
- Tobevibart plus elebsiran in hepatitis D: crossing a therapeutic threshold.
Crespo J, Cabezas J · Transl Gastroenterol Hepatol 2026
- Tobevibart plus elebsiran for the treatment of hepatitis D: how should we read the phase 2 data?
Kushner T, Reau N · Transl Gastroenterol Hepatol 2026
- Combination therapeutics for hepatitis delta virus infection: implications of the tobevibart-elebsiran SOLSTICE phase 2 trial.
Block PD, Lim JK · Transl Gastroenterol Hepatol 2026
- VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial.
Gane E, Wong GL, Currie S, et al. · Lancet Microbe 2026
- Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models.
Noack J, Anglero-Rodriguez Y, Gall J, et al. · Antimicrob Agents Chemother 2026
Also in development for Viral Hepatitis
- ElebsiranVIR-2218, BRII-835Phase 38 trials
Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Chronic Hepatitis B Virus (HBV) Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.